VJHemOnc is committed to improving our service to you

ASH 2019 | Oral time-limited duvelisib/venetoclax in R/R CLL

VJHemOnc is committed to improving our service to you

Matthew Davids

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the phase I trial (NCT03534323) assessing duvelisib in combination with venetoclax as a possible treatment for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). Early efficacy data for this 1-year time-limited, all oral regimen are promising. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter